Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–33 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed No phase listed Observational Accepts healthy volunteers

Database Surveillance Safety Study of PENTACEL® Vaccine

NCT00804284
Conditions
Diphtheria, Tetanus, Pertussis, Haemophilus Influenzae
Interventions
DTaP-IPV/Hib, Other DTap Vaccines
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Weeks to 24 Months · Male only
Enrollment
62,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Oakland, California
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Completed Phase 4 Interventional Results available

Tdap Vaccine in Post-Partum Women

NCT01711645
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Fluarix®, Boostrix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years and older
Enrollment
1,726 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
12
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

NCT01311557
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 11 Years
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
34
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, Boostrix
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
13
States / cities
Tucson, Arizona • San Diego, California • Stockbridge, Georgia + 9 more
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
10 Years and older
Enrollment
1,363 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 16 more
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more